文献速递胸部肿瘤

奥希替尼联合德达博妥单抗治疗EGFR突变晚期NSCLC一线奥希替尼耐药后:ORCHARD研究

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
PubMed 文献 · Ann Oncol · 2026-03-02

ORCHARD平台研究评估奥希替尼联合Dato-DXd在EGFR突变晚期NSCLC一线奥希替尼进展后的疗效与安全性。6 mg/kg队列不良事件频率和严重程度更高但可管理,综合获益风险建议6 mg/kg作为联合奥希替尼80 mg的首选起始剂量。

要点

  • 奥希替尼联合Dato-DXd在奥希替尼耐药后显示临床获益。
  • 6 mg/kg队列中位PFS 11.7个月,中位OS 26.2个月。
  • 6 mg/kg队列≥3级AE 76%,需预防、监测和剂量调整。

核心结论

  • 奥希替尼联合Dato-DXd在EGFR突变晚期NSCLC一线奥希替尼进展后显示临床获益,综合获益风险建议6 mg/kg为联合奥希替尼80 mg的首选Dato-DXd起始剂量。

研究设计与样本

  • ORCHARD(NCT03944772)是一项II期平台研究,旨在表征一线奥希替尼进展后的耐药机制并评估新型治疗组合。
  • 本报告为奥希替尼联合Dato-DXd模块的最终数据,纳入EGFR突变晚期NSCLC且一线奥希替尼进展的患者。
  • 主要终点为研究者按RECIST v1.1评估的确认客观缓解率(ORR),次要终点包括无进展生存期(PFS)、缓解持续时间(DoR)、总生存期(OS)和安全性。

主要发现

  • 4 mg/kg队列(N=35)确认ORR为43%(80% CI 32%至55%),6 mg/kg队列(N=34)为36%(80% CI 25%至49%)。
  • 4 mg/kg和6 mg/kg队列中位PFS分别为9.5个月(95% CI 7.2-9.8个月)和11.7个月(95% CI 8.3-21.7个月)。
  • 4 mg/kg和6 mg/kg队列中位DoR分别为6.3个月(95% CI 3.8-8.1个月)和20.5个月(95% CI 6.2个月-不可计算;估计中位至少16个月)。
  • 4 mg/kg和6 mg/kg队列中位OS分别为19.8个月(95% CI 13.5-23.3个月)和26.2个月(95% CI 14.8个月-不可计算;估计中位不低于4 mg/kg队列)。
  • 4 mg/kg和6 mg/kg队列分别有49%和76%患者报告≥3级不良事件(AE),导致Dato-DXd剂量降低的AE分别为23%和59%,裁定间质性肺病/肺炎分别为3%和15%。

关键数值与推荐

  • 确认ORR:4 mg/kg队列43%(80% CI 32%至55%),6 mg/kg队列36%(80% CI 25%至49%)。
  • 中位PFS:4 mg/kg队列9.5个月(95% CI 7.2-9.8个月),6 mg/kg队列11.7个月(95% CI 8.3-21.7个月)。
  • 中位OS:4 mg/kg队列19.8个月(95% CI 13.5-23.3个月),6 mg/kg队列26.2个月(95% CI 14.8个月-不可计算)。
  • ≥3级AE:4 mg/kg队列49%,6 mg/kg队列76%;裁定间质性肺病/肺炎:4 mg/kg队列3%,6 mg/kg队列15%。

临床怎么用

  • 对于EGFR突变晚期NSCLC一线奥希替尼进展后的患者,可考虑奥希替尼联合Dato-DXd治疗。
  • 综合获益风险特征,建议Dato-DXd起始剂量选择6 mg/kg联合奥希替尼80 mg。
  • 6 mg/kg队列AE频率和严重程度较高,可通过预防、仔细监测和剂量降低进行管理。

局限性

  • 6 mg/kg队列的DoR和OS置信区间较宽且上限不可计算,估计值需谨慎解读。
  • 安全性特征与各药物已知特征一致,但联合用药的长期安全性需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ORCHARD (NCT03944772) was a phase II platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations following progressive disease (PD) on first-line osimertinib. Datopotamab deruxtecan (Dato-DXd) is an anti-TROP2 antibody-drug conjugate approved as monotherapy in EGFR-mutated advanced non-small-cell lung cancer (NSCLC). We report final data from the osimertinib plus Dato-DXd module. METHODS: Eligible patients had EGFR-mutated advanced NSCLC and PD on first-line osimertinib. Patients received oral osimertinib (80 mg once daily) plus intravenous Dato-DXd (4 or 6 mg/kg every 3 weeks). The primary endpoint was investigator-assessed confirmed objective response rate (ORR) per RECIST v1.1. Secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall survival (OS), and safety. RESULTS: Sixty-nine patients received study treatment. Among patients in the 4 mg/kg (N = 35) and 6 mg/kg (N = 34) cohorts, respectively, confirmed ORR was 43% [80% confidence interval (CI) 32% to 55%] and 36% (80% CI 25% to 49%); median PFS was 9.5 months (95% CI 7.2-9.8 months) and 11.7 months (95% CI 8.3-21.7 months); median DoR was 6.3 months (95% CI 3.8-8.1 months) and 20.5 months [95% CI 6.2 months-not calculable (NC); estimated median of at least 16 months]; and median OS was 19.8 months (95% CI 13.5-23.3 months) and 26.2 months (95% CI 14.8 months-NC; estimated median greater than or equal to the 4 mg/kg cohort). In the 4 mg/kg and 6 mg/kg cohorts, respectively, grade ≥3 adverse events (AEs) were reported in 49% and 76% of patients; AEs leading to Dato-DXd dose reduction in 23% and 59%; and adjudicated interstitial lung disease/pneumonitis in 3% and 15%. CONCLUSIONS: Osimertinib plus Dato-DXd demonstrated clinical benefit in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib. AEs in the 6 mg/kg cohort were of higher frequency and severity but could be managed with prophylaxis, careful monitoring, and dose reduction. The safety profile was consistent with the known profiles of the individual drugs. Considering the overall benefit-risk profile, 6 mg/kg is suggested as the preferred Dato-DXd starting dose for combining with osimertinib 80 mg. CLINICAL TRIAL NUMBER: ClinicalTrials.govNCT03944772.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Riess JW, Yu HA, Le X, et al. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. Ann Oncol. 2026. PMID: 41780641. doi:10.1016/j.annonc.2026.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。